There is no answer that can satisfy you. You are locked

New Post Public Reply Private Reply Replies (2) Message Board
Bhawks smackles #17607
There is no answer that can satisfy you. You are locked into the unsupportable assertion that Obama simply didn't belong at Columbia U., Harvard law, U. of C. Law, the U.S. Senate and in the Presidency.

A reasonable person looks at that kind of progression and doesn't give a flying f*ck about college grades, and doesn't NEED to delegitimize someone that they didn't vote for.

GWB'S Harvard Business degree. Anything about that and his abysmal job creation record and the reat Recession raise questions in your mind about his grades?

Quote:
Obama's admission to Harvard Law School demonstrably wasn't tainted by the notion that he didn't belong there: He made sure of that by graduating magna cum laude, his peers selected him editor of the Harvard Law Review, and classmates and professors gush on and on about how impressed they were by the guy.

Then there's the institution's perspective. Harvard University is obsessed with training future leaders. In Barack Obama, they got a United States Senator ... and we haven't even gotten to the obvious argument, as offered by Matt Yglesias:

If it's true that Barack Obama couldn't get into college without a boost from affirmative action, then the fact that he later went on to become President of the United States of America would surely go to show that affirmative action is a good idea! The concern that super-talented people were getting locked out of opportunities is exactly the sort of thing affirmative action is supposed to resolve.


Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Huawei Introduces Innovative Wearables for Enhanced Connectivity

Updated Category News Views 293

Huawei Unveils Next-Generation Wearables and Tablets At a much-anticipated event, Huawei Consumer Business Group (CBG) revealed a thrilling array of new products. This launch showcased a strong emphasis on trendy wearables and sophisticated tablets, highlighting the brand's dedication to innovation and a user-friendly design. Chic Wearables for Style and Utility Among the...

Continue Reading
Investigating Barnes & Noble Education: Shareholder Rights Explained

Updated Category News Views 155

Understanding the Investigation of Barnes & Noble Education In a proactive move for investors, the law firm Bragar Eagel & Squire, P.C. is currently investigating Barnes & Noble Education, Inc. (BNED). This investigation aims to determine whether the company potentially breached federal securities laws or engaged in unlawful business practices that could lead to...

Continue Reading
Bailey Kennedy Achieves Landmark Legal Win for Talisman Group

Updated Category News Views 171

Bailey Kennedy Achieves Legal Victory for Talisman Group Judge Rules LNW Violated Talisman's Distribution Agreement by Marketing Competing Game In a significant legal development, Bailey Kennedy, LLP has successfully represented The Talisman Group, LLC, the innovative minds behind EZ Baccarat. The firm has recently triumphed in a legal dispute against LNW Gaming, Inc.,...

Continue Reading
Join the Class Action Lawsuit Against Ardelyx, Inc. Now

Updated Category News Views 49

Join the Class Action Lawsuit Against Ardelyx, Inc. Attention Ardelyx, Inc. investors! There's an important class action lawsuit underway, and this is your opportunity to get involved. Bronstein, Gewirtz & Grossman, LLC, a respected law firm known for its dedication to investor advocacy, has announced a class action case involving Ardelyx, Inc. (NASDAQ: ARDX) and certain...

Continue Reading
Aileron Therapeutics Unveils Q3 2024 Financial Performance

Updated Category News Views 97

Aileron Therapeutics Reports Impressive Q3 2024 Financial Results Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical company committed to developing innovative medicines for orphan pulmonary diseases, has recently showcased significant progress with their third-quarter financial results. This quarter has been marked by promising advancements in clinical trials...

Continue Reading